CD274 and neoplasm: Although several studies demonstrated a genetically divergence [e.g., higher rates of BRAF mutations, higher tumor mutational burden (TMB), higher PD-L1 expression, private gene mutations] between brain metastases and their primary tumors [26–28], no significant differences were observed in mutation profiles between a case series of breast cancer brain metastases and their primary lesions [29].